United States Oral Solid Dosage Contract Manufacturing Market to Grow with a CAGR of 5.72% through 2029

Growing Prevalence of Chronic Diseases is expected to drive the United States Oral Solid Dosage Contract Manufacturing Market growth in the forecast period, 2025-2029.

According to TechSci Research report, "United States Oral Solid Dosage Contract Manufacturing Market - By Region, Competition Forecast & Opportunities, 2029F", the United States Oral Solid Dosage Contract Manufacturing Market stood at USD 8.46 billion in 2023 and is anticipated to grow with a CAGR of 5.72% through 2029. The rising prevalence of chronic diseases is a key driver of growth in the United States Oral Solid Dosage Contract Manufacturing Market. As these conditions become more widespread, there is an increasing demand for oral solid dosage forms, such as tablets and capsules, benefiting contract manufacturing organizations (CMOs) that produce these products. The incidence of chronic diseases like diabetes, cardiovascular disorders, obesity, gastrointestinal issues, and respiratory conditions is on the rise in the U.S. These conditions typically require long-term medication, creating sustained demand for oral solid dosage forms. Pharmaceutical companies depend on contract manufacturers to efficiently produce these medications at scale.

The aging population in the U.S. is a significant factor contributing to the rise of chronic diseases. As people age, they become more vulnerable to conditions like hypertension, arthritis, and type 2 diabetes, leading to an increased need for reliable, effective oral solid medications. This demographic shift further drives the demand for contract manufacturing services to meet this growing need.

Chronic conditions usually require ongoing treatment, often involving daily medication. Oral solid dosage forms are preferred for their convenience, ease of use, and cost-effectiveness, making them the preferred choice for managing chronic diseases. This long-term need for medications contributes to a stable, growing demand for contract manufacturing services.

As the burden of chronic diseases drives up healthcare costs, the healthcare industry is seeking more cost-effective solutions. Contract manufacturers play a critical role in helping pharmaceutical companies manage production expenses while ensuring accessibility of medications for the increasing population of individuals with chronic conditions.

Additionally, many chronic diseases require specialized formulations, such as extended-release or combination therapies, to manage symptoms and enhance patient outcomes. As drug treatments become more complex, the demand for contract manufacturers capable of producing high-quality, customized oral solid dosage forms continues to grow. Beyond treatment medications, chronic disease management often involves preventive drugs to reduce complications, further increasing the need for oral solid dosage forms. As the incidence of chronic diseases continues to rise, the role of contract manufacturers in meeting the demand for these medications becomes even more essential.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "UnitedStates Oral Solid Dosage Contract Manufacturing Market”

The United States Oral Solid Dosage Contract Manufacturing Market is segmented into mechanism, product type, end-user, regional distribution, and company. 

Based on End-User, Large Size Companies emerged as the dominating segment in the United States Oral Solid Dosage Contract Manufacturing Market in 2023. Large companies possess the financial strength to invest in cutting-edge manufacturing facilities, advanced technologies, and specialized production capabilities. These investments enable them to efficiently scale production, which is essential to meet the high demand for oral solid dosage forms. In addition, major pharmaceutical companies typically have established global distribution networks and are involved in the production of both branded and generic drugs. This extensive reach facilitates significant outsourcing to contract manufacturers, particularly for oral solid dosage forms, ensuring a continuous demand for these services. Furthermore, large companies often have robust R&D departments, enabling them to develop a broad range of oral solid dosage formulations. This capability leads to increased demand for contract manufacturers capable of producing a variety of complex drug formulations, such as extended-release tablets, combination therapies, and treatments for chronic conditions. Large pharmaceutical companies also tend to enter into long-term, high-volume agreements with contract manufacturing organizations (CMOs), benefiting from the ability to produce large quantities of medications at competitive prices. These long-term partnerships provide stability and growth opportunities for CMOs, further solidifying the dominance of large companies in the market. Additionally, large firms have the necessary resources to ensure adherence to stringent regulatory requirements, such as those imposed by the FDA, ensuring that products are produced safely and meet all regulatory standards.

Based on Region, South emerged as the fastest growing region in the United States Oral Solid Dosage Contract Manufacturing Market during the forecast period. The South is becoming a key hub for pharmaceutical manufacturing, with states such as North Carolina, Georgia, Texas, and Florida leading the way in the healthcare and life sciences industries. These states are increasingly drawing pharmaceutical companies due to their lower operating costs, favorable business environments, and access to a skilled workforce. The region also benefits from a growing infrastructure that supports large-scale manufacturing and efficient distribution, which is vital for the production and delivery of oral solid dosage forms. The well-developed transportation networks, including ports and highways, facilitate the smooth movement of raw materials and finished products, further enhancing the region’s attractiveness for pharmaceutical contract manufacturing.

Substantial investments in healthcare, biotechnology, and pharmaceutical research, particularly in states like Texas and North Carolina, are driving growth in the contract manufacturing sector. As local pharmaceutical companies look to meet the demand for oral solid dosage forms, they are increasingly outsourcing production. The South offers more competitive labor and operational costs compared to regions like the Northeast or West Coast, making it an appealing choice for contract manufacturers. These lower costs enable the production of oral solid dosage forms at more competitive prices, which further fuels demand for manufacturing services. Additionally, the growth of pharmaceutical and biotech clusters, such as North Carolina’s Research Triangle and Texas’ Life Sciences Corridor, is attracting both large pharmaceutical companies and contract manufacturers. These clusters promote collaboration and innovation, creating an ideal environment for the expansion of contract manufacturing services, particularly for oral solid dosage forms.

Major companies operating in United States Oral Solid Dosage Contract Manufacturing Market are:

• Catalent, Inc.
• Lonza Group
• AbbVie Inc.
• Aenova Group
• Adare Pharma Solutions
• Boehringer Ingelheim International GmbH
• Jubilant Pharmova Limited
• Patheon Pharma Services
• Recipharm AB
• Corden Pharma International

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The U.S. Oral Solid Dosage Contract Manufacturing Market is experiencing significant growth, fueled by the rising demand for oral medications driven by the increasing prevalence of chronic diseases. As pharmaceutical companies seek more cost-effective production options, outsourcing to contract manufacturers has become a strategic move. The market is further supported by innovations in drug formulations, including extended-release and combination therapies, along with advancements in manufacturing technologies. With a supportive regulatory environment and continuous investment in healthcare infrastructure, the U.S. remains a leading market, attracting both domestic and international pharmaceutical companies in need of scalable, high-quality manufacturing solutions”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“United States Oral Solid Dosage Contract Manufacturing Market By Product Type (Tablets, Capsules, Powders, Granules, Others), By Mechanism (Immediate Release, Delayed Release, Controlled Release), By End-user (Large Size Companies, Medium & Small Size Companies, Others), Region and Competition, Opportunity, and Forecast, 2019-2029F”, has evaluated the future growth potential of United States Oral Solid Dosage Contract Manufacturing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Oral Solid Dosage Contract Manufacturing Market.

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com